ABL Diagnostics announced that its reference shareholder, Advanced Biological Laboratories (ABL) S.A., has crossed below the threshold of 95% of the company's capital. Following various block trade transactions executed since 2025, ABL S.A. now holds 93.58% of the capital and 95.90% of the voting rights. This reduction marks a new milestone in the free float expansion strategy initiated by ABL since taking control of the company in October 2021 and reaffirmed during the 2022 merger. The strategy aims to broaden the shareholder base, improve stock liquidity, and enhance visibility among stakeholders.

The prospectus approved by the French Financial Markets Authority (AMF) on July 12, 2022, under visa number 22-296, outlined ABL's intention to expand the free float to potentially up to 30% of the share capital. Despite the reduction, ABL remains the majority shareholder and reaffirms its support for ABL Diagnostics' development strategy and international expansion. The company continues to focus on molecular diagnostics and infectious diseases, marketing products such as UltraGene and DeepChek® globally through its own sales team and exclusive distributors.

ABL Diagnostics serves academic clinical pathology laboratories, private reference laboratories, and researchers. The company has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. Its expanding portfolio includes HIV drug resistance testing, advanced detection solutions for SARS-CoV-2 and Tuberculosis, and microbiome analyses.

The company offers integrated solutions such as real-time syndromic PCR tests and Nadis®, a patient medical record used in over 200 hospitals in France. Headquartered in Woippy, ABL Diagnostics is a public limited company listed on compartment B of the regulated market of Euronext in Paris. Its molecular biology products generate recurring revenues and cover a large portfolio of applications in microbiology.

Key Details of the Filing

ABL Diagnostics shareholders approved a dividend of €0.11 per share for the 2025 fiscal year, an increase from €0.05 per share in the 2024 fiscal year. The decision was made at the Annual General Meeting held on June 30, 2026. The higher dividend reflects the company's improved results and strong financial position.

The dividend will be ex-dividend on July 3, 2026, and will be paid on July 7, 2026. The approval was part of a series of resolutions passed by shareholders during the meeting.

ABL Diagnostics specializes in innovative molecular biology tests and global solutions. Its product portfolio includes Molecular polymerase chain reaction (PCR) detection under the UltraGene brand and genotyping by DNA sequencing under the DeepChek® brand.

The company markets its products globally through its own sales team and a network of exclusive distributors. Its customers include academic clinical pathology laboratories, private reference laboratories, and researchers.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement. The company is headquartered in Woippy and is listed on Euronext in Paris.

Dividend Details

Key Dates